Element Biosciences unveiled Vitari, a high‑throughput sequencing platform designed to produce ~3 terabases per paired‑end 150 bp run in 36 hours and to sequence a 30× human genome for a claimed $100 cost. The company positioned Vitari as its first high‑throughput instrument targeting routine, lower‑cost whole‑genome workflows. Element says the platform combines throughput and economics to expand access for population sequencing and clinical genomics; the company highlighted run time and per‑genome cost as competitive differentiators. Early adopters and cost‑modelers will evaluate throughput, accuracy, and total cost of ownership relative to incumbent systems. If Vitari delivers on claimed metrics at scale, it could pressure sequencing economics across research and diagnostic markets and accelerate large‑cohort genomic programs.